Full-Time

Controller

Remix Therapeutics

Remix Therapeutics

11-50 employees

Biotech firm developing mRNA-degrading therapies

Compensation Overview

$188k - $240k/yr

+ Bonus + Equity

Watertown, MA, USA

In Person

Bachelor's

Category
Accounting (1)
Required Skills
NetSuite
ERP

Get referred to Remix Therapeutics

See people who can refer or advise you

Requirements
  • A bachelor's degree in Accounting or Finance.
  • An active Certified Public Accountant license.
  • At least 10 years of progressive accounting experience with increasing leadership responsibility.
  • Big Four public accounting experience combined with biotechnology, pharmaceutical, or life sciences industry experience.
  • Strong knowledge of United States Generally Accepted Accounting Principles and operational accounting.
  • Experience managing the monthly close process.
  • Experience supporting annual audits and working with external auditors.
  • Experience developing accounting processes, controls, and scalable financial operations.
  • Enterprise resource planning experience; NetSuite is preferred.
  • Strong operational accounting expertise.
  • Excellent organizational and project management skills.
  • Collaborative leadership and a team-first mindset.
  • High integrity and attention to detail.
  • Ability to build scalable processes in a fast-paced environment.
  • Strong communication skills.
  • A hands-on approach balanced with strategic thinking.
Responsibilities
  • Lead all day-to-day accounting operations, including the general ledger, accounts payable, payroll accounting, fixed assets, lease accounting, cash, prepaid expenses, accruals, and other core accounting functions.
  • Own the monthly, quarterly, and annual financial close process, ensuring timely and accurate financial information.
  • Review journal entries, account reconciliations, and supporting schedules.
  • Ensure compliance with United States Generally Accepted Accounting Principles and company accounting policies.
  • Oversee accounting for equity transactions, intercompany activity if applicable, and other routine accounting matters.
  • Continuously improve close efficiency through automation, standardization, and process improvements.
  • Deliver complete, accurate trial balances and supporting schedules for quarterly and annual external reporting.
  • Partner with the SEC Reporting Manager on quarterly and annual reporting activities by providing accounting support, schedules, disclosures, and audit documentation.
  • Collaborate on implementation of new accounting standards and support required financial disclosures.
  • Support preparation of Audit Committee and executive financial reporting materials.
  • Develop, implement, and maintain effective accounting processes and internal controls over transaction processing and financial operations.
  • Partner with the SEC Reporting Manager on the design, implementation, documentation, and ongoing maintenance of the Company's Sarbanes-Oxley compliance program and internal controls over financial reporting.
  • Serve as the process owner for key accounting business cycles, ensuring controls are operating effectively and supporting Sarbanes-Oxley testing and remediation efforts.
  • Collaborate with the SEC Reporting Manager, external auditors, and process owners to identify control enhancements, address deficiencies, and implement remediation plans as needed.
  • Drive continuous process improvements that strengthen the control environment while improving operational efficiency.
  • Help establish scalable accounting policies, procedures, and controls appropriate for a newly public biotechnology company.
  • Serve as the primary operational contact for the Company's external auditors.
  • Coordinate annual financial statement audits and quarterly review procedures.
  • Prepare and review audit schedules and supporting documentation.
  • Coordinate with external tax advisors to support income tax, sales tax, and other statutory filings.
  • Ensure compliance with company accounting policies and applicable financial regulations.
  • Oversee cash accounting, banking activities, and treasury operations.
  • Maintain oversight of payroll processing and accounts payable.
  • Lead implementation and optimization of accounting systems and financial technologies.
  • Ensure accounting systems support accurate reporting and strong internal controls.
  • Build, mentor, and develop a high-performing accounting team.
  • Manage outsourced accounting resources while developing an internal organization appropriate for the Company's growth.
  • Foster a culture of accountability, collaboration, continuous improvement, and operational excellence.
  • Partner closely with Finance, Legal, Human Resources, Clinical Operations, Research, Procurement, and other business functions.
Desired Qualifications
  • Experience supporting an initial public offering or operating within a newly public company.
  • Experience building accounting teams in a high-growth organization.
  • Experience transitioning accounting functions from outsourced providers to an internal team.
  • Experience with biotechnology accounting, including clinical trial accruals, manufacturing, licensing agreements, collaboration arrangements, and equity compensation accounting.

Remix Therapeutics develops medicines for rare diseases with a focus on targeted mRNA degradation. Its lead product REM 422 is an oral small molecule that degrades messenger RNA to stop production of disease-causing proteins. REM 422 is in Phase 1 trials for Adenoid Cystic Carcinoma and Acute Myeloid Leukemia, with FDA Orphan Drug Designation to support development. Remix funds its R&D through grants and partnerships, aiming to bring safe, effective therapies to patients and expand its portfolio.

Company Size

11-50

Company Stage

Growth Equity (Venture Capital)

Total Funding

$224.7M

Headquarters

Cambridge, Massachusetts

Founded

2018

Get referred to Remix Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • June 24, 2026 financing raised $100 million, funding operations into 2028.
  • SEC filing on August 6, 2026 confirms closing path and 2028 runway.
  • 2027 registrational ACC data and AML/HR-MDS readouts create multiple catalysts.

What critics are saying

  • December 24, 2026 is the outside date; failure kills the Passage merger.
  • REM-422 dominates value; any weak 2027 ACC or AML data crushes valuation.
  • Passage holders receive only 7% ownership, signaling leverage and integration fragility.

What makes Remix Therapeutics unique

  • REM-422 targets MYB, a historically undruggable cancer driver, with oral dosing.
  • June 24, 2026 merger preserves Remix’s RNA-processing platform and Nasdaq access.
  • Remaster platform reprograms RNA processing, creating multiple shots on goal beyond REM-422.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

0%

2 year growth

4%
Pharma Journalist
Jun 25th, 2026
Remix Therapeutics to merge with Passage Bio.

Remix Therapeutics to merge with Passage Bio. On Jun 25, 2026 Remix Therapeutics and Passage Bio have agreed to merge in an all-stock transaction, creating a combined biotechnology company focused on advancing RNA-targeted therapies for cancer and other serious diseases. The deal is backed by a new $100 million private financing, providing the merged company with the resources needed to advance its clinical pipeline through several key development milestones. Following the completion of the transaction, the combined company will operate under the name Remix Therapeutics, Inc. and is expected to trade on the Nasdaq stock exchange under the ticker symbol "RMTX." Alongside the merger announcement, Remix revealed that it has secured commitments for an oversubscribed private placement financing led by Decheng Capital, with participation from Lynx1 Capital Management, Forge Life Science Partners, existing investors, and several other institutional investment firms. The financing is expected to close immediately before the merger is finalized. The combined company expects its cash position, including proceeds from the private placement, to fund operations into 2028. The funding is intended to support several important clinical milestones, including data from the registrational Phase 2 trial of REM-422 in Adenoid Cystic Carcinoma (ACC), results from a Phase 1 trial evaluating the therapy in Acute Myeloid Leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS), as well as continued investment in Remix's discovery pipeline. The merger strengthens Remix's position as it develops a new class of small-molecule medicines designed to modulate RNA processing. Unlike conventional therapies that target proteins directly, Remix's platform focuses on controlling how RNA is processed inside cells, offering the potential to treat diseases driven by genetic abnormalities that have historically been difficult to target with existing drugs. At the center of the company's pipeline is REM-422, an orally administered mRNA degrader that targets MYB, a transcription factor involved in several cancers. MYB has long been considered one of the most challenging cancer targets for drug developers, making REM-422 a potentially significant advance if ongoing clinical studies continue to produce positive results. Peter Smith, Ph.D., co-founder and Chief Executive Officer of Remix Therapeutics, described the merger as a transformative milestone for the company. He said the transaction provides the financial strength and operational support needed to accelerate the development of RNA-targeted medicines while expanding the company's proprietary platform. Smith added that the financing and merger position Remix to rapidly advance REM-422 and other pipeline candidates, with the goal of delivering innovative treatment options for patients with cancers that currently have limited therapeutic choices. For Passage Bio, the agreement follows an extensive review of strategic alternatives aimed at maximizing shareholder value. President and Chief Executive Officer Dr. Will Chou said Remix emerged as the ideal partner because of its differentiated RNA processing technology and encouraging early clinical data for REM-422 in adenoid cystic carcinoma. Chou noted that the ongoing registrational study, combined with the company's experienced leadership team, offers Passage Bio shareholders the opportunity to participate in a clinical-stage biotechnology company with a clearly defined path toward pivotal clinical data. The merger reflects growing investor confidence in RNA-based drug development, an area that has attracted increasing attention across the biotechnology industry. By combining Passage Bio's public company infrastructure with Remix's clinical-stage pipeline and fresh capital, the new organization aims to accelerate the development of innovative RNA-targeted therapies and expand treatment options for patients with difficult-to-treat cancers.

BioSpace
Jun 25th, 2026
Passage Bio and Remix Therapeutics Announce Merger Agreement

Combined company to operate as Remix Therapeutics and advance Remix’s pipeline of novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin

Boston Cambridge Biotech Networks
Jun 25th, 2026
Remix Therapeutics secures $100M and a reverse merger.

Remix Therapeutics secures $100M and a reverse merger. June 25, 2026 BCBN news, syndication comments off on remix therapeutics secures $100M and a reverse merger. The deal with Passage Bio includes commitments for $100 million in private placement financing led by Decheng Capital. Click here to view original post

MarketScreener
Jun 24th, 2026
Passage Bio and Remix Therapeutics merge in $100M deal to advance RNA cancer therapies

Passage Bio and Remix Therapeutics have announced a definitive merger agreement, with the combined company to operate as Remix Therapeutics and trade on Nasdaq under ticker symbol "RMTX". Upon closing, pre-merger Passage Bio shareholders will own approximately 7% of the combined entity, whilst Remix stockholders will hold 93%. Concurrent with the merger, Remix has secured an oversubscribed $100 million private placement financing led by Decheng Capital. The funding is expected to support operations into 2028 and deliver several clinical readouts for Remix's lead programme, REM-422, an orally available mRNA degrader targeting MYB, in 2027. The transaction, unanimously approved by both boards, is expected to close in the fourth quarter of 2026, subject to shareholder approval and customary closing conditions. The combined company will be led by Remix CEO Peter Smith.

The Manila Times
Nov 3rd, 2025
Remix Therapeutics to Present at Guggenheim Second Annual Healthcare Innovation Conference

Remix Therapeutics to present at Guggenheim Second Annual Healthcare Innovation Conference. WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) - Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, will present a corporate overview at the Guggenheim Second Annual Healthcare Innovation Conference on November 10, 2025 at 2:15 PM ET The Remix management team will also be hosting one-on-one meetings with investors. For those investors interested in scheduling a meeting, please contact your Guggenheim representative. About Remix Therapeutics Remix Therapeutics is a clinical-stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin. Remix's REMaster(TM) technology platform leverages cutting-edge data science, biomolecular sciences and chemistry approaches to identify orally administered compounds that modulate gene expression. Remix's innovative therapeutic approach led to the discovery of REM-422, a first-in-class RNA processing modulator in oncology, now being evaluated in Phase 1 clinical studies to treat acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (HR-MDS) and adenoid cystic carcinoma (ACC). For more information visit www.remixtx.com.